Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients
Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modu...
Saved in:
| Published in: | Neuropsychiatric disease and treatment Vol. 20; pp. 1435 - 1444 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New Zealand
Dove Medical Press Limited
01-01-2024
Dove Dove Medical Press |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls.
The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers.
The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. |
|---|---|
| AbstractList | Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls.BackgroundSchizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls.The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers.ResultsThe methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers.The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients.ConclusionThe study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls. The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers. The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients. Mary Angelin,1 Padmavathi Gopinath,1 Vijaya Raghavan,1,2 Rangaswamy Thara,2 Faraz Ahmad,3 Arasamabattu Kannan Munirajan,1 Ravi Sudesh4 1Department of Genetics, University of Madras, Dr ALM PG Institute of Basic Medical Sciences, Taramani Campus, Chennai, Tamil Nadu, 600 113, India; 2Schizophrenia Research Foundation, Chennai, Tamil Nadu, 600 101, India; 3Department of Biotechnology, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India; 4Department of Biomedical Sciences, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, IndiaCorrespondence: Ravi Sudesh, Department of Biomedical Sciences, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India, Tel +91-9176028134, Email sudesh.ravi@vit.ac.in; sudesh.genetics@gmail.com Arasamabattu Kannan Munirajan, Department of Genetics, Dr. ALM PG Institute Basic Medical Sciences, University of Madras, Taramani, Chennai, Tamil Nadu, 600 113, India, Tel +91-44-24547064 ; +91-9444460136, Email akmunirajan@gmail.com; akmunirajan@unom.ac.inBackground: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic marks, which regulate gene expression and cause an array of systemic changes. Several studies have demonstrated the association of epigenetic modulations in schizophrenia, which can influence clinical course, symptoms, and even treatment. Based on this, we have examined the global DNA methylation patterns, namely the 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC); and the global RNA modification N6-methyladenosine (m6A) RNA methylation status in peripheral blood cells. First-Episode Psychosis (FEP) patients who were diagnosed with Schizophrenia (SCZ) and undergoing treatment were stratified as Treatment-Responsive (TR) and Treatment-Non-Responsive (TNR). Age- and sex-matched healthy subjects served as controls.Results: The methylation pattern of 5mC and 5hmC showed significant increases in patients in comparison to controls. Further, when patients were classified based on their response to treatment, there was a statistically significant increase in methylation patterns in the treatment non-responder group. 5fC and m6A levels did not show any statistical significance across the groups. Further, gender-based stratification did not yield any significant difference for the markers.Conclusion: The study highlights the increased global methylation pattern in SCZ patients and a significant difference between the TR versus TNR groups. Global 5mC and 5hmC epigenetic marks suggest their potential roles in schizophrenia pathology, and also in the treatment response to antipsychotics. Since not many studies were available on the treatment response, further validation and the use of more sensitive techniques to study methylation status could unravel the potential of these epigenetic modifications as biomarkers for SCZ as well as distinguishing the antipsychotic treatment response in patients.Keywords: schizophrenia, global methylation, treatment response, 5mC, 5hmC, m6A |
| Audience | Academic |
| Author | Ahmad, Faraz Sudesh, Ravi Gopinath, Padmavathi Thara, Rangaswamy Munirajan, Arasamabattu Kannan Raghavan, Vijaya Angelin, Mary |
| Author_xml | – sequence: 1 givenname: Mary orcidid: 0000-0003-0624-6530 surname: Angelin fullname: Angelin, Mary organization: Department of Genetics, University of Madras, Dr ALM PG Institute of Basic Medical Sciences, Taramani Campus, Chennai, Tamil Nadu, 600 113, India – sequence: 2 givenname: Padmavathi surname: Gopinath fullname: Gopinath, Padmavathi organization: Department of Genetics, University of Madras, Dr ALM PG Institute of Basic Medical Sciences, Taramani Campus, Chennai, Tamil Nadu, 600 113, India – sequence: 3 givenname: Vijaya surname: Raghavan fullname: Raghavan, Vijaya organization: Schizophrenia Research Foundation, Chennai, Tamil Nadu, 600 101, India – sequence: 4 givenname: Rangaswamy surname: Thara fullname: Thara, Rangaswamy organization: Schizophrenia Research Foundation, Chennai, Tamil Nadu, 600 101, India – sequence: 5 givenname: Faraz orcidid: 0000-0003-4284-8045 surname: Ahmad fullname: Ahmad, Faraz organization: Department of Biotechnology, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India – sequence: 6 givenname: Arasamabattu Kannan orcidid: 0000-0003-1337-9008 surname: Munirajan fullname: Munirajan, Arasamabattu Kannan organization: Department of Genetics, University of Madras, Dr ALM PG Institute of Basic Medical Sciences, Taramani Campus, Chennai, Tamil Nadu, 600 113, India – sequence: 7 givenname: Ravi surname: Sudesh fullname: Sudesh, Ravi organization: Department of Biomedical Sciences, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39049939$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkktv1DAUhSNURB-wYo-8QkhVih-JHa_QqC8qlYI6w9pynJuJq4wdbA9o-uvxdIaKrq5lH3065_ocFwfOOyiK9wSfUVKJz3cXi7N5xXmN6aviiBDRlBRTcvB05iVntDksjmN8wJgJ2TRvikMmcSUlk0fFn-vRt3pEF3czpF2H7vP8BmnYjDpZ79DcLp1O6wDIOnQPcfIuAkoezVyyU9yYwSdr0CKATitwaSu7siGm8nKy0XeA5mawj34aAjir0Y-MzbL4tnjd6zHCu_08KX5eXS7Ov5a3369vzme3pWFcpLJucUOBcdlrJkHmKFXPOtGbtgYhtTCGyVpg03eQc7OKEa5FX7W0MQIkEHZS3Oy4ndcPagp2pcNGeW3V04UPS6VDTjCCAgwZ30nZYVNB12rS5DXWXNe4BdrRzPqyY03rdgWdyTmCHl9AX744O6il_60IobwRVZUJn_aE4H-tISa1stHAOGoHfh0Vw00luBCSZ-nHnXSps7cB9JiG6Mf19leimjVY0iavaOvqdCc0wccYoH82RLDaFkTlgqh9QbL6w_8ZnrX_GsH-Ag7YuSE |
| Cites_doi | 10.1186/s13578-023-01167-4 10.1111/j.1600-0447.2005.00659.x 10.1016/j.neuron.2018.07.009 10.1016/B978-0-12-813939-4.00025-5 10.1016/j.psychres.2017.08.022 10.1007/s12017-012-8198-6 10.1016/j.jad.2019.02.009 10.1038/s41588-021-00890-3 10.3389/fpsyg.2016.01496 10.1016/j.pnpbp.2019.109855 10.1038/npp.2012.125 10.1016/j.jpsychires.2019.04.001 10.1038/s41392-020-00420-3 10.1101/pdb.prot5439 10.1016/j.tibs.2013.07.003 10.2217/epi-2017-0086 10.1038/clpt.2012.152 10.3389/fnins.2021.674273 10.3389/fgene.2018.00243 10.1016/j.jpsychires.2021.03.003 10.2217/epi-2023-0017 10.1016/j.schres.2008.01.009 10.1080/13102818.2014.933501 10.3389/fgene.2017.00100 10.1038/jhg.2012.140 10.1002/phar.2375 10.2217/epi-2019-0350 10.1007/s12033-020-00269-5 10.1016/j.jpsychires.2006.08.006 10.1007/s00702-022-02585-3 10.1016/j.pnpbp.2017.10.004 10.1038/s41380-019-0601-3 10.1016/S0140-6736(18)32279-7 10.2217/epi-2020-0451 |
| ContentType | Journal Article |
| Copyright | 2024 Angelin et al. COPYRIGHT 2024 Dove Medical Press Limited 2024 Angelin et al. 2024 Angelin et al. |
| Copyright_xml | – notice: 2024 Angelin et al. – notice: COPYRIGHT 2024 Dove Medical Press Limited – notice: 2024 Angelin et al. 2024 Angelin et al. |
| DBID | NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.2147/NDT.S466502 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Angelin et al |
| EISSN | 1178-2021 |
| EndPage | 1444 |
| ExternalDocumentID | oai_doaj_org_article_e0e284d99d0c4edba1802156a50be2d2 A809283672 10_2147_NDT_S466502 39049939 |
| Genre | Journal Article |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 0YH 123 29N 2WC 53G 5VS 7RV 7X7 8AO 8FE 8FH 8FI 8FJ 8G5 ABIVO ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BKEYQ BPHCQ BVXVI CCPQU CS3 DIK DWQXO E3Z EBD EBS EJD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO IHR IHW IPNFZ IPY ITC KQ8 LK8 M2M M2O M48 M7P M~E NAPCQ NPM O5R O5S OK1 P2P P6G PIMPY PQQKQ PROAC PSYQQ RIG RNS RPM TDBHL TR2 UKHRP VDV AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c367t-5b082e369fa39e93284f3d7fcb5e79a7cc39570cfde17834316a7f4b28c7e9e13 |
| IEDL.DBID | RPM |
| ISSN | 1176-6328 1178-2021 |
| IngestDate | Tue Oct 22 15:02:30 EDT 2024 Tue Sep 17 21:27:49 EDT 2024 Sat Oct 26 04:33:56 EDT 2024 Tue Sep 24 02:23:17 EDT 2024 Sat Sep 14 00:15:37 EDT 2024 Sat Nov 02 12:23:33 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | 5hmC m6A 5mC schizophrenia global methylation treatment response |
| Language | English |
| License | 2024 Angelin et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c367t-5b082e369fa39e93284f3d7fcb5e79a7cc39570cfde17834316a7f4b28c7e9e13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-1337-9008 0000-0003-0624-6530 0000-0003-4284-8045 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268744/ |
| PMID | 39049939 |
| PQID | 3084767796 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e0e284d99d0c4edba1802156a50be2d2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11268744 proquest_miscellaneous_3084767796 gale_healthsolutions_A809283672 crossref_primary_10_2147_NDT_S466502 pubmed_primary_39049939 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand |
| PublicationTitle | Neuropsychiatric disease and treatment |
| PublicationTitleAlternate | Neuropsychiatr Dis Treat |
| PublicationYear | 2024 |
| Publisher | Dove Medical Press Limited Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
| References | De Luca (ref39) 2023; 130 Kinoshita (ref17) 2013; 15 Mao (ref25) 2023; 12 Wu (ref27) 2023; 13 Karthiya (ref23) 2020; 62 Jiang (ref3) 2021; 6 Zhou (ref10) 2021; 15 (ref34) 2017 Alelú-Paz (ref9) 2016; 7 Swathy (ref12) 2018; 10 Han (ref24) 2020; 14 (ref2) 2019 Torabi Moghadam (ref19) 2019; 114 van Os (ref28) 2006; 113 Shi (ref31) 2017; 8 Jiang (ref32) 2017; 257 Swathy (ref13) 2019; 2 Lokmer (ref37) 2023; 15 Burghardt (ref11) 2020; 40 Grayson (ref6) 2013; 38 Engel (ref22) 2018; 99 Murata (ref14) 2020; 99 Hack (ref1) 2019; 249 Shimabukuro (ref33) 2007; 41 Ivanov (ref15) 2012; 92 Song (ref16) 2013; 38 Marques (ref38) 2020; 12 Reszka (ref4) 2021; 137 Ovenden (ref5) 2018; 81 Xiong (ref26) 2021; 53 Rio (ref30) 2010; 2010 Bromberg (ref35) 2008; 101 Loureiro (ref20) 2021; 13 Smigielski (ref7) 2020; 25 Rukova (ref36) 2014; 28 Nishioka (ref18) 2013; 58 (ref29) 1998 Romano (ref21) 2018; 9 James (ref8) 2018; 392 |
| References_xml | – volume: 13 start-page: 1 year: 2023 ident: ref27 publication-title: Cell Biosci doi: 10.1186/s13578-023-01167-4 contributor: fullname: Wu – volume: 113 start-page: 91 year: 2006 ident: ref28 publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.2005.00659.x contributor: fullname: van Os – volume: 12 start-page: 1127 year: 2023 ident: ref25 publication-title: EC Psychol Psychiatry contributor: fullname: Mao – volume: 99 start-page: 389 year: 2018 ident: ref22 publication-title: Neuron doi: 10.1016/j.neuron.2018.07.009 contributor: fullname: Engel – volume: 2 start-page: 733 year: 2019 ident: ref13 publication-title: Pharmacoepigenetics doi: 10.1016/B978-0-12-813939-4.00025-5 contributor: fullname: Swathy – volume: 257 start-page: 497 year: 2017 ident: ref32 publication-title: Psychiatry Res doi: 10.1016/j.psychres.2017.08.022 contributor: fullname: Jiang – volume: 15 start-page: 95 year: 2013 ident: ref17 publication-title: NeuroMolecular Med doi: 10.1007/s12017-012-8198-6 contributor: fullname: Kinoshita – volume: 249 start-page: 336 year: 2019 ident: ref1 publication-title: J Affect Disord doi: 10.1016/j.jad.2019.02.009 contributor: fullname: Hack – volume: 53 start-page: 1156 year: 2021 ident: ref26 publication-title: Nat Genet doi: 10.1038/s41588-021-00890-3 contributor: fullname: Xiong – volume: 7 start-page: 1 year: 2016 ident: ref9 publication-title: Front Psychol doi: 10.3389/fpsyg.2016.01496 contributor: fullname: Alelú-Paz – volume: 99 start-page: 109855 year: 2020 ident: ref14 publication-title: Prog Neuro Psychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2019.109855 contributor: fullname: Murata – volume: 38 start-page: 138 year: 2013 ident: ref6 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2012.125 contributor: fullname: Grayson – volume: 114 start-page: 41 year: 2019 ident: ref19 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2019.04.001 contributor: fullname: Torabi Moghadam – volume: 6 start-page: 3 year: 2021 ident: ref3 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-020-00420-3 contributor: fullname: Jiang – volume: 2010 start-page: 5439 year: 2010 ident: ref30 publication-title: Cold Spring Harb Protoc doi: 10.1101/pdb.prot5439 contributor: fullname: Rio – volume: 38 start-page: 480 year: 2013 ident: ref16 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2013.07.003 contributor: fullname: Song – volume: 10 start-page: 233 year: 2018 ident: ref12 publication-title: Epigenomics doi: 10.2217/epi-2017-0086 contributor: fullname: Swathy – volume: 92 start-page: 727 year: 2012 ident: ref15 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2012.152 contributor: fullname: Ivanov – volume: 15 start-page: 674273 year: 2021 ident: ref10 publication-title: Front Neurosci doi: 10.3389/fnins.2021.674273 contributor: fullname: Zhou – volume: 9 start-page: 7 year: 2018 ident: ref21 publication-title: Front Genet doi: 10.3389/fgene.2018.00243 contributor: fullname: Romano – volume-title: At the Bench a Laboratory Navigator First year: 1998 ident: ref29 – volume: 137 start-page: 283 year: 2021 ident: ref4 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2021.03.003 contributor: fullname: Reszka – volume: 15 start-page: 3 year: 2023 ident: ref37 publication-title: Epigenomics doi: 10.2217/epi-2023-0017 contributor: fullname: Lokmer – volume: 101 start-page: 1 year: 2008 ident: ref35 publication-title: Schizophr Res doi: 10.1016/j.schres.2008.01.009 contributor: fullname: Bromberg – volume: 28 start-page: 518 year: 2014 ident: ref36 publication-title: Biotechnol Biotechnol Equip doi: 10.1080/13102818.2014.933501 contributor: fullname: Rukova – volume: 8 start-page: 100 year: 2017 ident: ref31 publication-title: Front Genet doi: 10.3389/fgene.2017.00100 contributor: fullname: Shi – volume: 58 start-page: 91 year: 2013 ident: ref18 publication-title: J Hum Genet doi: 10.1038/jhg.2012.140 contributor: fullname: Nishioka – volume: 40 start-page: 331 year: 2020 ident: ref11 publication-title: Pharmacotherapy doi: 10.1002/phar.2375 contributor: fullname: Burghardt – volume: 12 start-page: 1041 year: 2020 ident: ref38 publication-title: Epigenomics doi: 10.2217/epi-2019-0350 contributor: fullname: Marques – volume: 62 start-page: 467 year: 2020 ident: ref23 publication-title: Mol Biotechnol doi: 10.1007/s12033-020-00269-5 contributor: fullname: Karthiya – volume-title: Nutritional Epigenomics year: 2019 ident: ref2 – volume: 41 start-page: 1042 year: 2007 ident: ref33 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2006.08.006 contributor: fullname: Shimabukuro – volume: 14 start-page: 1 year: 2020 ident: ref24 publication-title: Front Neurosci contributor: fullname: Han – volume: 130 start-page: 165 year: 2023 ident: ref39 publication-title: J Neural Transm doi: 10.1007/s00702-022-02585-3 contributor: fullname: De Luca – volume: 81 start-page: 38 year: 2018 ident: ref5 publication-title: Prog Neuro Psychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2017.10.004 contributor: fullname: Ovenden – volume: 25 start-page: 1718 year: 2020 ident: ref7 publication-title: Mol Psychiatry doi: 10.1038/s41380-019-0601-3 contributor: fullname: Smigielski – volume-title: DNA Methylation, Hydroxymethylation and Formylation in Human Frontal Cortex of Autistic and Schizophrenic Subjects year: 2017 ident: ref34 – volume: 392 start-page: 1789 year: 2018 ident: ref8 publication-title: Lancet doi: 10.1016/S0140-6736(18)32279-7 contributor: fullname: James – volume: 13 start-page: 927 year: 2021 ident: ref20 publication-title: Epigenomics doi: 10.2217/epi-2020-0451 contributor: fullname: Loureiro |
| SSID | ssj0037988 |
| Score | 2.3777084 |
| Snippet | Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter epigenetic... Background: Schizophrenia is a heterogeneous chronic psychiatric disorder influenced by genetic and environmental factors. Environmental factors can alter... Mary Angelin,1 Padmavathi Gopinath,1 Vijaya Raghavan,1,2 Rangaswamy Thara,2 Faraz Ahmad,3 Arasamabattu Kannan Munirajan,1 Ravi Sudesh4 1Department of Genetics,... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1435 |
| SubjectTerms | 5hmc 5mc Analysis Antipsychotic drugs DNA Drug therapy Epigenetic inheritance Ethylenediaminetetraacetic acid Gene expression Genes global methylation Health aspects m6a Methylation Methyltransferases Original Research RNA Schizophrenia treatment response |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgD4gL4k14GmmvYR07je1joa32shXaFomb5ccEcklXtBV_n5k6rRpx4MIpUmJFjmcy84098w1jl42BGKqJLr2u2hLxrS-9DKZEX43gpFJetbSVfb3Sy-9mNieanFOrL8oJy_TAeeGuQABa0GRtErGGFDxRlmHQ4ScigEzZ-gpzDKayDVbEwpWr8agPz9Vytv60qhtEI3Lkfw40_X8b4zNvNM6UPHM9i8fs0YAZ-TTP9Qm7B_1T9uBmOBV_xn5n4n4-W0657xO_xesNoARynhtfdT8yfyfven6bk2KB7zZ82u-6oQyri3x9zDmnYYsOYWE5v-u2mwR8dZ6ax79mLtbtc_ZtMV9_uS6HhgplVI3elZOADh9UY1uvLCByM3Wrkm5jmIC2XsdIp3YitgkqasChqsbrtg7SRA0WKvWCXfSbHl4xLgW0UkIVoMYIMyiDuBIEvkTUtZU-FuzyuMzuLvNmOIw3SBoOpeEGaRTsM4ngNITIrg83UAXcoALuXypQsA8kQJcrR0-_rJsaYRE9NRpHfDzK1uHvQ2civofNfuuUQPfcaG2bgr3Msj5NRlmKB5UtmBlpwWi24yd99_NA0U2FWdRY4PX_-L437KFEKJU3ft6yi92vPbxj97dp__6g9X8ATfMILQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Global DNA and RNA Methylation Signature in Response to Antipsychotic Treatment in First-Episode Schizophrenia Patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39049939 https://www.proquest.com/docview/3084767796 https://pubmed.ncbi.nlm.nih.gov/PMC11268744 https://doaj.org/article/e0e284d99d0c4edba1802156a50be2d2 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09b9swECXqDEWXok364X4kLJBVtkTKpDi6sY0sNoLYBboRJHVKBSSSEdvo3-9RlAwL3TIJkCiB0Dvy3pF3j4RciwycTSYyMjIpIuS3JjLMZhH6aiQnCTe88EvZt2u5-p3N5l4mR3S1ME3SvrPlqHp8GlXlnya3cvvkxl2e2PhueePLXrxs-3hABkgOuxg9zL_cK3CFI1VEJDjLQlWeP49nvJptRutUICthPT_UyPX_PymfeKV-xuSJC1q8I29b7kinoY_vySuozsnrZbs7fkH-BgF_OltNqalyeo_XJSASId-NrsuHoONJy4reh-RYoPuaTqt92ZZjlY5uutxz32xRIj2M5ttyV-dA16cpevQuaLLuPpBfi_nm5jZqD1aIHBdyH00sOn7gQhWGK0AGl6UFz2Xh7ASkMtI5v3sXuyKHxB_EwRNhZJFaljkJChL-kZxVdQWfCWUxFIxBYiHFSNPyDPklxPiROE0VM25IrrvfrLdBP0Nj3OHR0IiGbtEYkp8egmMTL3rd3KifH3QLvYYYsKe5UnnsUsit8ep1GH-aSWyB5fiRKw-gDhWkx6Grp1mskEUJiS1-dNhqHEZ-b8RUUB92msfopoWUSgzJp4D1sTNc-biQqyHJelbQ623_CVpuI9XdWeqXl7_6lbxhSKTCss83crZ_PsB3Mtjlh8tmAeGysf5_XlkJ1g |
| link.rule.ids | 230,315,729,782,786,866,887,2108,27935,27936,53803,53805 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdrB9te9t0t-6oGfXUiW45kPWZNQsaaUJoM9iYk-dwZVjs0Cfv3d7LskLC3PhksWQjfSfc76e53hFyIDJyNhzIyMi4ixLcmMonNIrTVCE5ibnjhj7JnS7n4lY0nniZHdLkwTdC-s2W_-nPXr8rfTWzl-s4NujixwfX80qe9eNr2wQl5jAuW8c5LDzsw9xxcoaiKiARPspCX5yvyDBbjVX-ZCsQlyZElagj7_9-WD-zScczkgRGavnjo9F-S5y3spKPQ_oo8guo1eTJvL9bfkL-B-5-OFyNqqpze4HMOKMQQKkeX5W2gAKVlRW9CXC3QbU1H1bZsM7lKR1dd2LrvNi0RWUaTdbmpc6DLw-g-eh3oXDdvyc_pZHU5i9qaDJHjQm6joUXMAFyownAFCP6ytOC5LJwdglRGOucv_pgrcoh9DQ8eCyOL1CaZk6Ag5mfktKoreE9owqBIEogtpOikWp4hNAWGg7A0VYlxPXLRyUevA_WGRpfFi1GjGHUrxh755mW37-L5spsX9f2tbn-7BgY401ypnLkUcms88R26rmbILCQ5DnLuJa9D8ul-1etRxhQCMCGxx9dOKTSuQH-tYiqodxvNGVp4IaUSPfIuKMl-Mlx5l5KrHsmO1OdotsctqDUNy3enJR8e_uk5eTpbza_01ffFj4_kWYJ4LJwefSKn2_sdfCYnm3z3pVk8_wC3jR6e |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db5swELfWTqr2su912Vc9qa8kYION95Y1iTptiaImk_ZmGXN0SCtETaL9-ztjiIL2tj0hgbEMd_b9zr77HSGXIgWbRYkMjIyKAPGtCQzL0gBtNYKTiBteuK3s65Vc_EgnU0eT86nLhWmC9m1WDqtfd8Oq_NnEVm7u7KiLExst51cu7cXRto82eTE6IQ9x0oZJ56n7VZg7Hi5fWEUEgrPU5-a5qjyjxWQ9XMUCsQnrWaOGtP_vpfnINvXjJo8M0ezJ_3zCU_K4hZ907Ns8Iw-gek7O5u0B-wvy29cAoJPFmJoqpzd4nQMK04fM0VV566lAaVnRGx9fC3RX03G1K9uMrtLSdRe-7prNSkSYwXRTbusc6Oo4yo8uPa3r9iX5Ppuur66DtjZDYLmQuyDJEDsAF6owXAGCwDQueC4LmyUglZHWugPA0BY5RK6WB4-EkUWcsdRKUBDxV-S0qit4TSgLoWAMogxidFYzniJEhRA7CeNYMWMH5LKTkd54Cg6NrosTpUZR6laUA_LZye_QxPFmNzfq-1vd_noNIeBIc6Xy0MaQZ8YR4KELa5IwA5ZjJxdO-tonoR5mvx6noUIgJiS2-NgphsaZ6I5XTAX1fqt5iJZeSKnEgJx7RTkMhivnWnI1IGlPhXqj7T9BzWnYvjtNefPvr16Qs-Vkpr99WXx9Sx4xhGV-E-kdOd3d7-E9Odnm-w_N_PkDr5EhHg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Global+DNA+and+RNA+Methylation+Signature+in+Response+to+Antipsychotic+Treatment+in+First-Episode+Schizophrenia+Patients&rft.jtitle=Neuropsychiatric+disease+and+treatment&rft.au=Angelin%2C+Mary&rft.au=Gopinath%2C+Padmavathi&rft.au=Raghavan%2C+Vijaya&rft.au=Thara%2C+Rangaswamy&rft.date=2024-01-01&rft.issn=1176-6328&rft.volume=20&rft.spage=1435&rft_id=info:doi/10.2147%2FNDT.S466502&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1176-6328&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1176-6328&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1176-6328&client=summon |